Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
P. Hammel(Université Paris Cité), Talia Golan(Sheba Medical Center), Hyun Kyoo Yoo(National Evidenc- based healthcare Collaborating Agency), David McGuinness(Université Paris Cité), Nikunj Patel(Nirma University), Anke Reinacher‐Schick(Ruhr University Bochum), Karen Cui(Université Paris Cité), S. Joo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joon Oh Park(Samsung Medical Center), Giampaolo Tortora(University of Naples Federico II), Michele Reni(San Raffaele University of Rome), Dirk Arnold(Asklepios Klinik Altona), Do‐Youn Oh(Seoul National University Hospital), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Daniel Hochhauser(Royal London Hospital), Hedy L. Kindler(University of Chicago), Eric Van Cutsem(Universitair Ziekenhuis Leuven), C. Michael Hall(Children's Hospital Colorado), Hana Algül(TUM Klinikum)
Cited by 44
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Pandemics, tourism and global change: a rapid assessment of COVID-19
|Journal of Sustainable Tourism|2020|4.6k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k